234 related articles for article (PubMed ID: 31223083)
1. Nanoparticles Functionalized with Venom-Derived Peptides and Toxins for Pharmaceutical Applications.
Dos Santos AP; de Araújo TG; Rádis-Baptista G
Curr Pharm Biotechnol; 2020; 21(2):97-109. PubMed ID: 31223083
[TBL] [Abstract][Full Text] [Related]
2. Animal toxins - Nature's evolutionary-refined toolkit for basic research and drug discovery.
Herzig V; Cristofori-Armstrong B; Israel MR; Nixon SA; Vetter I; King GF
Biochem Pharmacol; 2020 Nov; 181():114096. PubMed ID: 32535105
[TBL] [Abstract][Full Text] [Related]
3. Venoms as a platform for human drugs: translating toxins into therapeutics.
King GF
Expert Opin Biol Ther; 2011 Nov; 11(11):1469-84. PubMed ID: 21939428
[TBL] [Abstract][Full Text] [Related]
4. Advances in venom peptide drug discovery: where are we at and where are we heading?
Smallwood TB; Clark RJ
Expert Opin Drug Discov; 2021 Oct; 16(10):1163-1173. PubMed ID: 33914674
[No Abstract] [Full Text] [Related]
5. Cell-Penetrating Peptides Derived from Animal Venoms and Toxins.
Rádis-Baptista G
Toxins (Basel); 2021 Feb; 13(2):. PubMed ID: 33671927
[TBL] [Abstract][Full Text] [Related]
6. Peptide therapeutics from venom: Current status and potential.
Pennington MW; Czerwinski A; Norton RS
Bioorg Med Chem; 2018 Jun; 26(10):2738-2758. PubMed ID: 28988749
[TBL] [Abstract][Full Text] [Related]
7. Venom peptides as therapeutics: advances, challenges and the future of venom-peptide discovery.
Robinson SD; Undheim EAB; Ueberheide B; King GF
Expert Rev Proteomics; 2017 Oct; 14(10):931-939. PubMed ID: 28879805
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological screening technologies for venom peptide discovery.
Prashanth JR; Hasaballah N; Vetter I
Neuropharmacology; 2017 Dec; 127():4-19. PubMed ID: 28377116
[TBL] [Abstract][Full Text] [Related]
9. Progress and challenges in the optimization of toxin peptides for development as pain therapeutics.
Netirojjanakul C; Miranda LP
Curr Opin Chem Biol; 2017 Jun; 38():70-79. PubMed ID: 28376346
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular-Active Venom Toxins: An Overview.
Rebello Horta CC; Chatzaki M; Rezende BA; Magalhães Bde F; Duarte CG; Felicori LF; Ribeiro Oliveira-Mendes BB; do Carmo AO; Chávez-Olórtegui C; Kalapothakis E
Curr Med Chem; 2016; 23(6):603-22. PubMed ID: 26812904
[TBL] [Abstract][Full Text] [Related]
11. High-throughput expression of animal venom toxins in Escherichia coli to generate a large library of oxidized disulphide-reticulated peptides for drug discovery.
Turchetto J; Sequeira AF; Ramond L; Peysson F; Brás JL; Saez NJ; Duhoo Y; Blémont M; Guerreiro CI; Quinton L; De Pauw E; Gilles N; Darbon H; Fontes CM; Vincentelli R
Microb Cell Fact; 2017 Jan; 16(1):6. PubMed ID: 28095880
[TBL] [Abstract][Full Text] [Related]
12. Breakthroughs in Venom Peptide Screening Methods to Advance Future Drug Discovery.
Napolitano T; Holford M
Protein Pept Lett; 2018; 25(12):1137-1148. PubMed ID: 30381057
[TBL] [Abstract][Full Text] [Related]
13. The Place for Enzymes and Biologically Active Peptides from Marine Organisms for Application in Industrial and Pharmaceutical Biotechnology.
Morlighem JRL; Radis-Baptista G
Curr Protein Pept Sci; 2019; 20(4):334-355. PubMed ID: 30255754
[TBL] [Abstract][Full Text] [Related]
14. Venom peptides as pharmacological tools and therapeutics for diabetes.
Robinson SD; Safavi-Hemami H
Neuropharmacology; 2017 Dec; 127():79-86. PubMed ID: 28689026
[TBL] [Abstract][Full Text] [Related]
15. Treating autoimmune disorders with venom-derived peptides.
Shen B; Cao Z; Li W; Sabatier JM; Wu Y
Expert Opin Biol Ther; 2017 Sep; 17(9):1065-1075. PubMed ID: 28695745
[TBL] [Abstract][Full Text] [Related]
16. Utilisation of compounds from venoms in drug discovery.
Trim CM; Byrne LJ; Trim SA
Prog Med Chem; 2021; 60():1-66. PubMed ID: 34147202
[TBL] [Abstract][Full Text] [Related]
17. Versatile spider venom peptides and their medical and agricultural applications.
Saez NJ; Herzig V
Toxicon; 2019 Feb; 158():109-126. PubMed ID: 30543821
[TBL] [Abstract][Full Text] [Related]
18. Snake Venom: From Deadly Toxins to Life-saving Therapeutics.
Waheed H; Moin SF; Choudhary MI
Curr Med Chem; 2017; 24(17):1874-1891. PubMed ID: 28578650
[TBL] [Abstract][Full Text] [Related]
19. Gene design, fusion technology and TEV cleavage conditions influence the purification of oxidized disulphide-rich venom peptides in Escherichia coli.
Sequeira AF; Turchetto J; Saez NJ; Peysson F; Ramond L; Duhoo Y; Blémont M; Fernandes VO; Gama LT; Ferreira LM; Guerreiro CI; Gilles N; Darbon H; Fontes CM; Vincentelli R
Microb Cell Fact; 2017 Jan; 16(1):4. PubMed ID: 28093085
[TBL] [Abstract][Full Text] [Related]
20. Harnessing the knowledge of animal toxins to generate drugs.
Zambelli VO; Pasqualoto KF; Picolo G; Chudzinski-Tavassi AM; Cury Y
Pharmacol Res; 2016 Oct; 112():30-36. PubMed ID: 26826284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
